IN2015DN03969A - - Google Patents

Info

Publication number
IN2015DN03969A
IN2015DN03969A IN3969DEN2015A IN2015DN03969A IN 2015DN03969 A IN2015DN03969 A IN 2015DN03969A IN 3969DEN2015 A IN3969DEN2015 A IN 3969DEN2015A IN 2015DN03969 A IN2015DN03969 A IN 2015DN03969A
Authority
IN
India
Prior art keywords
treatments
methods
disorders
neuropathic
risk
Prior art date
Application number
Other languages
English (en)
Inventor
Steven James Harper
David Owen Bates
Melissa Gammons
Jonathan Morris
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1218676.3A external-priority patent/GB201218676D0/en
Priority claimed from GBGB1218758.9A external-priority patent/GB201218758D0/en
Priority claimed from GB201304694A external-priority patent/GB201304694D0/en
Application filed by Univ Bristol filed Critical Univ Bristol
Publication of IN2015DN03969A publication Critical patent/IN2015DN03969A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN3969DEN2015 2012-10-17 2013-10-17 IN2015DN03969A (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1218676.3A GB201218676D0 (en) 2012-10-17 2012-10-17 Anti-angiogenic treatments
GBGB1218758.9A GB201218758D0 (en) 2012-10-18 2012-10-18 Compounds
GB201304694A GB201304694D0 (en) 2013-03-15 2013-03-15 Compounds
PCT/GB2013/052716 WO2014060763A1 (en) 2012-10-17 2013-10-17 Compounds useful for treating ocular neovasculan

Publications (1)

Publication Number Publication Date
IN2015DN03969A true IN2015DN03969A (de) 2015-10-02

Family

ID=49518992

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3969DEN2015 IN2015DN03969A (de) 2012-10-17 2013-10-17

Country Status (8)

Country Link
US (1) US10301264B2 (de)
EP (1) EP2908811B1 (de)
JP (2) JP2016504270A (de)
CN (1) CN104869990B (de)
AU (1) AU2013333657B2 (de)
ES (1) ES2858511T3 (de)
IN (1) IN2015DN03969A (de)
WO (1) WO2014060763A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406956D0 (en) * 2014-04-17 2014-06-04 Univ Nottingham Compounds
GB201518365D0 (en) 2015-10-16 2015-12-02 Exonate Ltd Compounds
EP3503883B1 (de) * 2016-08-24 2022-05-04 National Institute Of Biological Sciences, Beijing Entacapon-assoziierte verbindungen zur behandlung von makuladegeneration
US11420969B2 (en) * 2017-09-27 2022-08-23 Exonate Limited SRPK1 inhibitors
GB202010829D0 (en) 2020-07-14 2020-08-26 Exonate Ltd Compounds for treatment of neovascular diseases
CN113769073A (zh) * 2021-10-15 2021-12-10 杭州鑫伟低碳技术研发有限公司 一种利用生物酶治疗眼底出血的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052507A (de) 1963-06-26
AU759310B2 (en) 1998-08-20 2003-04-10 Agouron Pharmaceuticals, Inc. Non-peptide GnRH agents, methods and intermediates for their preparation
FR2840314B1 (fr) 2002-06-03 2004-08-20 Inst Francais Du Petrole Methode d'isolation thermique, procede de preparation d'un gel isolant et gel isolant obtenu
EP1712242B1 (de) * 2003-12-26 2018-05-30 Masatoshi Hagiwara Verfahren zur regulierung der phosphorylierung von sr-protein und sr-protein-aktivitätsregulator als wirkstoff enthaltende antivirale mittel
US7880000B2 (en) * 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
WO2007072041A1 (en) * 2005-12-23 2007-06-28 Astex Therapeutics Limited Therapeutic compounds
US20100213228A1 (en) 2006-07-18 2010-08-26 Thule Sweden Ab System and method for providing an article organizer to a recreational vehicle
AU2007336781C1 (en) * 2006-12-21 2014-10-09 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009020198A1 (ja) * 2007-08-03 2009-02-12 Kinopharma, Inc. 抗ｄｎａウイルス作用を有するアニリン誘導体
CN101422603A (zh) 2007-10-31 2009-05-06 马万超 不溶性生物活性蛋白质作为玻璃体内用药治疗眼科疾病
GB0803912D0 (en) 2008-02-29 2008-05-07 Univ Bristol Novel Uses of VEGFxxxb
EP2279750A4 (de) * 2008-03-25 2012-09-26 Kinopharma Inc Anilin-derivat mit anti-rna-viraler wirkung
EP2358382A2 (de) 2008-11-22 2011-08-24 The University of Bristol Neue verwendungen für vegfxxxb
WO2011036429A1 (en) 2009-09-25 2011-03-31 The University Of Bristol Detection of risk of pre-eclampsia
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
GB201009173D0 (en) 2010-05-28 2010-07-14 Univ Bristol Treatment of pain
EP2632462A1 (de) * 2010-10-29 2013-09-04 Merck Sharp & Dohme Corp. Neue heteroaryl-carboximid-derivate als pdk1-hemmer
GB201406956D0 (en) * 2014-04-17 2014-06-04 Univ Nottingham Compounds

Also Published As

Publication number Publication date
JP2016504270A (ja) 2016-02-12
AU2013333657B2 (en) 2018-04-26
US10301264B2 (en) 2019-05-28
AU2013333657A1 (en) 2015-05-28
US20150274668A1 (en) 2015-10-01
EP2908811B1 (de) 2020-12-09
CN104869990A (zh) 2015-08-26
JP2018203748A (ja) 2018-12-27
WO2014060763A1 (en) 2014-04-24
ES2858511T3 (es) 2021-09-30
CN104869990B (zh) 2022-12-20
EP2908811A1 (de) 2015-08-26
JP6738512B2 (ja) 2020-08-12

Similar Documents

Publication Publication Date Title
EP3297644A4 (de) Verfahren zur behandlung von störungen des autismusspektrums und damit verbundener symptome
EP3295404A4 (de) Verschleierung von absichten bei transaktionen unter verwendung von verschlüsselungstechniken
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
EP2756740A4 (de) Kaltplasmabehandlungsvorrichtungen und zugehörige verfahren
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
IN2015DN03969A (de)
EP3008167A4 (de) Zusammensetzungen und verfahren zur behandlung von stoffwechselstörungen
EP3041577A4 (de) Behandlung und verhütung von autismus und autismusspektrumserkrankungen
ZA201300954B (en) Methods for treating and/or reversing neurodegenerative deseases and/or disorders
EP2986308A4 (de) Angiotensin ii allein oder in kombination zur bekämpfung von hypotonie
SI2854910T1 (sl) Nivoji ceramida pri zdravljenju in preprečevanju okužb
IL233141A0 (en) Combined treatment of hearing and balance disorders
EP3068492A4 (de) Neurodegenerative erkrankungen und verfahren zur behandlung und diagnose
EP3099638A4 (de) Abwasserbehandlungsverfahren und system
EP2825194A4 (de) Verwendung von antithrombin bei der behandlung von präeklampsie
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
HUE041418T2 (hu) Aromás vegyületek és alkalmazásuk csont metabolizmushoz kapcsolódó rendellenességek kezelésére
HK1218882A1 (zh) 用於治療神經退化疾病和其它疾病的組合治療劑和方法
MX356052B (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
EP3010524A4 (de) Protamin bei der behandlung von nervenverletzungen
AU2014353885A8 (en) Prevention and treatment of toxicosis
EP3021944A4 (de) Igf-1r signalweginhibitoren zur behandlung von neurodegenerativen erkrankungen
PL2686005T3 (pl) Kompozycje do podawania miejscowego zawierające diaminooksydazę do leczenia lub zapobiegania chorobom związanym z wysokimi poziomami histaminy, które obejmują nasilenie bólu